Charlotte-Paige Rolle

12PUBLICATIONS
13CO-AUTHORS
Pharmaceutical delivery technologiesSeparation technologiesPharmacogenomicsGene and molecular therapyAboriginal and Torres Strait Islander theory of change models for health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 30, 2026
Rapid Virologic Suppression With Dolutegravir Plus Lamivudine Facilitates Early Switch to Long-Acting Cabotegravir Plus Rilpivirine for Treatment-Naive People With HIV-1: Month 11/12 Outcomes From the Phase 3b VOLITION Study.

|Jun 12, 2026
Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

|Sep 02, 2025
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.

Peter A Leone, Alejandro Ferro, Charlotte-Paige Rolle

|Mar 26, 2025
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials.

Charlotte-Paige Rolle, José R Arribas, Roberto Ortiz

|Mar 11, 2025
Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks.

Charlotte-Paige Rolle, Jeffrey Garrett, Jamie Castano

|Oct 17, 2024
Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study.

Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen

Pageof 2

Frequent Collaborators

2 joint publications

Pedro Cahn

1 joint publications

Federico Hinestrosa

1 joint publications

Marina Klein

1 joint publications

Margaret Gartland